Results 111 to 120 of about 621,963 (341)
Clinical Pharmacology &Therapeutics, EarlyView.Pharmacogenomic research has historically focused on individuals of European ancestry, leading to the underrepresentation of genetic variants common in non‐European populations. This bias is exemplified by CYP3A5*6, a functionally consequential variant common in individuals of African ancestry (MAF: 11–19%) but virtually absent in Europeans (MAF: 0.15%)
Amar D. Levens +10 more
wiley +1 more source
New Aspects of Thromboangiitis obliterans (von Winiwarter-Buerger's Disease) [PDF]
, 1984 The existence of thromboangiitis obliterans as a clinical entity has been a matter of debate for many years. In contrast to other immunovasculitides there is no organ involvement while peripheral vessels are affected.
Berlit, Peter +3 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Limited evidence exists synthesizing the risk of acute kidney injury (AKI) associated with the concomitant administration of multiple nephrotoxic drugs, and even less examining the concept of nephrotoxic burden. The objective of this scoping review was to (1) identify definitions of nephrotoxic burden; (2) methods used to quantify (use of calculations)
Wafa Alatawi +6 more
wiley +1 more source
Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. [PDF]
, 2018 Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 ...
Bourgeois, Bryan C +4 more
core +1 more source
Alteration of cystic airway mesenchyme in congenital pulmonary airway malformation. [PDF]
, 2019 Congenital pulmonary airway malformation (CPAM) is the most common congenital lesion detected in the neonatal lung, which may lead to respiratory distress, infection, and pneumothorax.
Jiang, Yi +9 more
core +3 more sources
EGR1 Nuclear Condensates Promote Renal Cyst Development in Polycystic Kidney Disease
Exploration, EarlyView.ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is marked by aberrant cell proliferation driven by cAMP‐PKA and MAPK signaling pathways. EGR1, a transcription factor directly activated by the above two pathways, is critical in the over‐proliferation of tumor cells, which share similarities with cystic epithelial cells in ADPKD. This study
Chaoqun Ren +15 more
wiley +1 more source
Journal of Cell Biology, 2008 Primary cilia project from the surface of most vertebrate cells and are thought to be sensory organelles. Defects in primary cilia lead to cystic kidney disease, although the ciliary mechanisms that promote and maintain normal renal function remain ...
J. Jonassen +3 more
semanticscholar +1 more source
Noninvasive Disease Diagnostics: The Swiss Contribution Highlights to Breath Analysis Research
Helvetica Chimica Acta, EarlyView.Breath analysis networks across Switzerland linking health monitoring, clinical applications, population studies, and data‐driven public health decisions. ABSTRACT To celebrate the 125th anniversary of the Swiss Chemical Society, we present a review and perspective to highlight the recent research in breath analysis that has been conducted in ...
Stefan James Swift +6 more
wiley +1 more source
Case Reports in Nephrology and DialysisIntroduction: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease, which is mainly caused by pathogenic variants in two particular genes: PKD1 and PKD2.
Tomáš Seeman +4 more
doaj +1 more source
BMC Nephrology, 2017 Background Patients with chronic kidney disease are at increased risk of cystic kidney disease that requires imaging monitoring in many cases. However, these same patients often have contraindications to contrast-enhanced computed tomography and magnetic
Emily Hueywen Chang +9 more
doaj +1 more source